Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Real-time Estimate Cboe BZX Other stock markets 11:18:46 2024-05-06 am EDT			5-day change	1st Jan Change
43.18 ^USD	-3.43%		+17.87%	+47.64%

May. 03	Sector Update: Health Care Stocks Mixed in Afternoon Trading	MT
May. 03	Tandem Diabetes Care Shares Rise After Q1 Net Loss Shrinks, Sales Rise; Q2, 2024 Sales Guidance Set	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	May. 03	MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	Apr. 29	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	Apr. 25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	Apr. 23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	Mar. 26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	Mar. 15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	Jan. 22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	Jan. 18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	23-10-18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	23-10-02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	23-10-02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	23-08-21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	23-08-21	MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating	23-08-07	MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating	23-08-07	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating	23-08-04	MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45	23-08-04	MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating	23-06-14	MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating	23-06-13	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Buy Rating	23-06-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Analyst Reco.

Filters